The spectrum expanded: cryptogenic cirrhosis and the natural history of non-alcoholic fatty liver disease.
about
Omega-3 polyunsaturated fatty acids for non-alcoholic fatty liver diseaseThe Natural Course of Non-Alcoholic Fatty Liver DiseaseThe Crosstalk between Hypoxia and Innate Immunity in the Development of Obesity-Related Nonalcoholic Fatty Liver Disease"Weighing the risk": Obesity and outcomes following liver transplantationNF-κB, JNK, and TLR Signaling Pathways in HepatocarcinogenesisNon-alcoholic fatty liver disease: epidemiology, clinical course, investigation, and treatment.Inflammation in nonalcoholic steatohepatitis.Noninvasive investigations for non alcoholic fatty liver disease and liver fibrosis.Age- and Gender Dependent Liver Fat Content in a Healthy Normal BMI Population as Quantified by Fat-Water Separating DIXON MR ImagingSerum oxidative stress markers and lipidomic profile to detect NASH patients responsive to an antioxidant treatment: a pilot study.Strong association between non alcoholic fatty liver disease (NAFLD) and low 25(OH) vitamin D levels in an adult population with normal serum liver enzymes.Non-viral causes of hepatocellular carcinoma.Treatment options for nonalcoholic Fatty liver diseaseRegulatable fatty acid transport mechanisms are central to the pathophysiology of obesity, fatty liver, and metabolic syndrome.Study of liver cirrhosis over ten consecutive years in Southern China.Nonalcoholic fatty liver disease and aging: epidemiology to management.Non-viral factors contributing to hepatocellular carcinoma.Clinical features and outcome of cryptogenic hepatocellular carcinoma compared to those of viral and alcoholic hepatocellular carcinoma.Genetic polymorphism of the human organic solute carrier protein 1 (hOSCP1) gene in Japanese patients with non-viral liver carcinoma.Characteristics of hepatocellular carcinoma in cirrhotic and non-cirrhotic non-alcoholic fatty liver disease.Decrypting cryptogenic hepatocellular carcinoma: clinical manifestations, prognostic factors and long-term survival by propensity score model.Glitazones for human nonalcoholic steatohepatitisManaging nonalcoholic fatty liver disease: recommendations for family physicians.Unexplained findings of kayser-fleischer-like rings in a patient with cryptogenic cirrhosis.A multi-mineral natural product inhibits liver tumor formation in C57BL/6 mice.Effect of miR-146 targeted HDMCP up-regulation in the pathogenesis of nonalcoholic steatohepatitisHistological assessment of non-alcoholic fatty liver disease.Evolution of hepatic steatosis in patients with advanced hepatitis C: results from the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial.Nonalcoholic fatty liver disease: from clinical recognition to treatment.KASL clinical practice guidelines: management of nonalcoholic fatty liver disease.Fibrogenesis in nonalcoholic steatohepatitis.Inflammation and fibrogenesis in steatohepatitis.Liver diseases and aging: friends or foes?Liver transplantation for nonalcoholic fatty liver disease: new challenges and new opportunities.Non-alcoholic fatty liver disease following liver transplantation: a clinical review.Significant decrease of saturation index in erythrocytes membrane from subjects with non-alcoholic fatty liver disease (NAFLD).Natural History of Nonalcoholic Fatty Liver Disease.Impact of family history of metabolic traits on severity of non-alcoholic steatohepatitis related cirrhosis: A cross-sectional study.The epidemiology of non-alcoholic fatty liver disease.Dietary sodium and potassium intake in relation to non-alcoholic fatty liver disease.
P2860
Q24202688-AB9263CB-8C03-48E1-B325-E5785F1B5B9BQ26746947-51E2C50B-5DC9-482D-A216-7215A7141033Q26780509-55418ACE-7D5A-4D87-B389-4D2EC93BB9F6Q26859205-8CFC8D88-FA83-4751-9B98-0336CA67E0ADQ28384956-DECF9334-9FD4-409D-AD30-F4CDAA69EBDCQ30434684-F2382307-16C4-43D6-933E-91364002BDC2Q30453231-899E8CF4-6542-4564-B9B5-4241D2FF9C5CQ30479092-5A4EE559-B883-43B9-ABC2-F79E7689A4D3Q31020766-EE54BAB5-D668-42CD-9BB8-DF9EE8F27A08Q33765372-678254F7-67EC-4B5A-A0E3-94D7D9625358Q33958775-99A96F0C-DAC3-45C3-A3E4-C7DF3B7DB801Q34041381-D519EB09-FD48-4494-B0C6-89DD886194BAQ34156317-6A37826C-1B3B-4715-BA0A-129313E82748Q34207748-CBE1432C-FCB1-4E1D-B546-31352D7E135CQ34303048-04707940-EFE2-433F-9B12-A08B11CE27BEQ34366861-90213A3A-939D-4068-A771-6BE7939E4098Q34653639-9A842CB4-B0DD-478E-8459-750899EC725BQ34799936-C81FC471-E2FF-4C87-8BF6-9D87D56B6090Q34878913-41833E82-879D-4B70-9263-A271327D3D4AQ35012074-7D7EBB40-6B9B-4E0C-8E97-BF60CA96612AQ35107166-0EEEEA2B-BBDA-4F4F-98B5-29F852A9F81FQ35191067-8FA44496-9606-4920-BD15-46FAD484F799Q35941934-CB0C1F1B-1B0D-48CF-94D2-A7905D754481Q35952585-41216822-F1F4-4058-964E-D5E626C75740Q35990259-BC96D1DB-89F2-4EA0-A51A-5972C6912EEAQ36323805-3411348F-9D01-413C-9925-A8B7AEAC4BA5Q36634377-CC1FC229-BD04-462E-90A3-C00C5E00D9CDQ37217299-BE9B26B9-02D2-4833-ABA1-E2AEE0CCB344Q37345907-C6A544C1-0C6E-4C7C-B339-5700244A9E61Q37488800-325775C1-525B-403B-A2FA-0D1CD7C86902Q37863130-BFEA558C-9AB1-455C-8448-259B8AF623B8Q37981867-121B2459-EE42-4BC9-9F4D-9659B4536C08Q38118358-7228161D-4A6E-4FE1-BE39-80724EE6FA73Q38212215-BD2023D9-F9D2-469B-872C-0A3C62B54297Q38543105-0937709A-3194-4B7F-A84F-62A8AA1D2681Q38613686-E78313BA-C22F-422B-95EA-95B8754D3C26Q38784787-EAD924D0-D474-4985-A369-C1E5FE349E46Q38945850-C65C3F30-E869-4982-AF97-BDF735CF2474Q39067325-8AE7B14B-23FC-4837-87BF-1B321A7A53CAQ39304864-16ECBDBE-8BA4-44F4-AA65-991E9AA20563
P2860
The spectrum expanded: cryptogenic cirrhosis and the natural history of non-alcoholic fatty liver disease.
description
2004 nî lūn-bûn
@nan
2004 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
The spectrum expanded: cryptog ...... alcoholic fatty liver disease.
@ast
The spectrum expanded: cryptog ...... alcoholic fatty liver disease.
@en
type
label
The spectrum expanded: cryptog ...... alcoholic fatty liver disease.
@ast
The spectrum expanded: cryptog ...... alcoholic fatty liver disease.
@en
prefLabel
The spectrum expanded: cryptog ...... alcoholic fatty liver disease.
@ast
The spectrum expanded: cryptog ...... alcoholic fatty liver disease.
@en
P1476
The spectrum expanded: cryptog ...... alcoholic fatty liver disease.
@en
P2093
Deborah M Crespo
Stephen H Caldwell
P304
P356
10.1016/J.JHEP.2004.02.013
P577
2004-04-01T00:00:00Z